Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism

This research was originally published in Blood Online. Edvardsen M, Hansen E, Hindberg K, Morelli VM, Ueland T, Aukrust P, Brækkan SK, Holtet Evensen L, Hansen JB. Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. Blood. 2021;138(...

Full description

Bibliographic Details
Published in:Blood
Main Authors: Edvardsen, Magnus, Hansen, Ellen-Sofie, Hindberg, Kristian, Morelli, Vania Maris, Ueland, Thor, Aukrust, Pål, Brækkan, Sigrid Kufaas, Holtet Evensen, Line, Hansen, John Bjarne
Format: Article in Journal/Newspaper
Language:English
Published: American Society of Hematology 2021
Subjects:
Online Access:https://hdl.handle.net/10037/24025
https://doi.org/10.1182/blood.2021011494
Description
Summary:This research was originally published in Blood Online. Edvardsen M, Hansen E, Hindberg K, Morelli VM, Ueland T, Aukrust P, Brækkan SK, Holtet Evensen L, Hansen JB. Combined effects of plasma von Willebrand factor and platelet measures on the risk of incident venous thromboembolism. Blood. 2021;138(22):2269-2277. Prepublished June 21, 2021; DOI https://doi.org/10.1182/blood.2021011494. Plasma von Willebrand factor (VWF) and platelet reactivity are risk factors for venous thromboembolism (VTE), and VWF can promote hemostasis by interaction with platelets. In this study, we explored the combined effects of plasma VWF and platelet measures on the risk of incident VTE. A population-based nested case-control study with 403 cases and 816 controls was derived from the Tromsø Study. VWF, platelet count and mean platelet volume (MPV) were measured in blood samples drawn at baseline. Odds ratios (ORs) with 95% confidence intervals (CIs) for VTE were estimated across VWF tertiles, within predefined MPV (<8.5, 8.5-9.5, and ≥9.5 fL) and platelet count (<230, 230-299, and ≥300 ×109/L) strata. Here, participants with VWF levels in the highest tertile and with MPV ≥9.5 fL had an OR of 1.98 (95% CI, 1.17-3.36) for VTE compared with those in the lowest VWF tertile and with MPV <8.5 fL in the age- and sex-adjusted model. In the joint exposure group, 48% (95% CI, 15-96) of VTEs were attributable to the biological interaction between VWF and MPV. Similarly, individuals with VWF in the highest tertile and platelet count ≥300 × 109/L had an OR of 2.91 (95% CI, 1.49-5.67) compared with those with VWF in the lowest tertile and platelet count <230 × 109/L, and 39% (95% CI, −2 to 97) of VTEs in the joint exposure group were explained by the interaction. Our results suggest that platelet reactivity and platelet count interact biologically with high plasma VWF, resulting in an increased risk for incident VTE.